Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection

Neurol Sci. 2017 Mar;38(3):501-502. doi: 10.1007/s10072-016-2726-3. Epub 2016 Oct 3.

Authors

Francesco Saccà¹, Chiara Pane², Anna De Rosa², Margherita Matarazzo³, Vincenzo Brescia Morra²

Affiliations

¹ Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Pansini, 5, 80131, Naples, Italy. francesco.sacca@unina.it.
² Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Pansini, 5, 80131, Naples, Italy.
³ Department of Translational Medical Sciences, University Federico II, Naples, Italy.

PMID: 27699497
DOI: 10.1007/s10072-016-2726-3

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Female
Fingolimod Hydrochloride / therapeutic use*
Hepatitis B / complications
Hepatitis B / drug therapy*
Humans
Immunosuppressive Agents / therapeutic use*
Lamivudine / therapeutic use*
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Reverse Transcriptase Inhibitors / therapeutic use*

Substances

Immunosuppressive Agents
Reverse Transcriptase Inhibitors
Lamivudine
Fingolimod Hydrochloride